Verastem (VSTM)
NASDAQ:VSTM
Want to see VSTM full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.43Last Year’s EPS
-0.39Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balanced encouraging commercial and R&D progress with near-term operational and financial challenges. Highlights include steady product revenue growth ($18.7M in Q1; nearly $50M to date), expanding prescriber base (>400), improved PK/tolerability and progression of the 7375 Target-D program into Phase II registration-directed trials across PDAC, NSCLC and CRC (900 mg go-forward dose), and a cash position of $181.7M with runway into H1 2027. Lowlights include seasonal/access headwinds and early discontinuations reducing short-term refill volumes, high R&D and SG&A relative to current revenue leading to continued non-GAAP net losses (~$42.7M), immature duration/refill metrics, and practical dosing/formulation constraints at higher VS-7375 doses. Overall, positives (pipeline advancement, reimbursement and commercial actions, and encouraging VS-7375 data) are significant but offset by meaningful execution and funding risks in the near term.Company Guidance
Commercial Launch Momentum and Revenue
Q1 2026 net product revenue of $18.7M and nearly $50M in total net product revenue to date; steady quarter-over-quarter growth since the May 2025 launch and management expects an increase from Q1 to Q2. Active prescribers expanded to more than 400 through April with a 60/40 split between GynOncs and MedOncs.
LGSOC Franchise Nearing Self-Sustainability
Company reiterates belief that the LGSOC franchise (AVMAPKI FAKZYNJA CO-PACK) will be self-sustaining in H2 2026, meaning CO-PACK revenues will support both commercial operations and ongoing clinical trials for avutometinib + defactinib.
Patient Access and Affordability Metrics
Approximately 65% of commercially eligible patients use the Verastem Cares Co-Pay Program; average co-pay for commercially insured patients is under $30. Time to fill initial prescriptions remains 12–14 days and payer mix is ~50% commercial / 50% Medicare.
Robust VS-7375 (Target-D) Clinical Program Advancement
VS-7375 Target-D program advanced: Target-D-101 Phase I/II ongoing (dose escalation up to 1,200 mg), and three Phase II registration-directed trials (Target-D 201 PDAC, 202 NSCLC, 203 CRC) initiated for 900 mg go-forward dose with primary endpoint overall response rate (BICR) and DOR as key secondary endpoint. First patients in Phase II anticipated mid-year.
PK and Tolerability Support Higher Go-Forward Dose
Updated PK data show 900 mg delivers serum levels at or above target with clear separation from 600 mg; 600 mg already showing responses. Tolerability in U.S. patients reported substantially better than previously reported China data (no significant liver dysfunction or hematologic issues observed to date).
Operational Leadership and Commercial Optimization
Appointment of experienced Chief Commercial Officer (Dan Lyons) and additional commercial personnel (including two added sales positions) plus launch of the 'Reimagine Recurrent LGSOC' physician/patient campaign and intensified post-scripture patient outreach to improve adherence and earlier use at first recurrence.
Balance Sheet and Runway
Cash, cash equivalents and investments of $181.7M at quarter end; company expects current cash plus future CO-PACK revenues to provide runway into the first half of 2027 (roughly ~12 months), and management is focused on nondilutive financing opportunities.
VSTM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VSTM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $5.66 | ― | ― |
Mar 04, 2026 | $5.81 | $6.15 | +5.85% |
Nov 04, 2025 | $9.90 | $7.91 | -20.10% |
Aug 07, 2025 | $5.62 | $6.74 | +19.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Verastem (VSTM) report earnings?
Verastem (VSTM) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Verastem (VSTM) earnings time?
Verastem (VSTM) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VSTM EPS forecast?
VSTM EPS forecast for the fiscal quarter 2026 (Q2) is -0.43.